Inducible nitric oxide synthase (iNOS) is responsible for nitric oxide (NO) synthesis, from L-arginine in response to inflammatory mediators. To determine the degradation pathway of iNOS, human epithelial kidney HEK293 cells with stable expression of human iNOS were incubated in the presence of various degradation pathway inhibitors. Treatment with the proteasomal inhibitors lactacystin, MG132 and ALLN resulted in accumulation of iNOS, indicating that these inhibitors blocked its degradation. Moreover, proteasomal inhibition blocked iNOS degradation in a dose and time dependent manner, as well as when NO synthesis was inhibited by L-NAME.
Introduction
Nitric oxide (NO) 1 , an important signaling and cytotoxic molecule, is synthesized from L- arginine by isoforms of nitric oxide synthase (NOS) (1, 2) . As a signaling molecule, NO is produced by two constitutive calcium (Ca 2+ )-dependent isoforms, neuronal NOS and endothelial NOS (or NOS1 and NOSIII, respectively). Ca 2+ -activated calmodulin binds to and transiently activates constitutive NOS dimers (2, 3) . Due to the transient nature of elevated Ca 2+ levels, the activity of NO produced is short-lived. As an agent of inflammation and cell-mediated immunity, NO is produced by a Ca 2+ -independent cytokine-inducible NOS (iNOS or NOSII) that is widely expressed in diverse cell types under transcriptional regulation by inflammatory mediators (4) (5) (6) .
Calmodulin is tightly bound to iNOS even at basal Ca 2+ levels and therefore iNOS is notably distinguished from the constitutive isoforms by its prolonged production of a relatively large amount of NO (7) . iNOS has been implicated in the pathogenesis of many diseases including
Alzheimer's disease, pulmonary tuberculosis, asthma, lung cancer, transplant rejection, cerebral infarct, glaucoma, bacterial pneumonia, inflammatory bowel disease, arthritis, and septic shock (8) (9) (10) .
The activity of an enzyme can be controlled through the regulation of its synthesis, catalytic activity, or degradation. Although much is known about factors affecting the synthesis and catalytic activity of iNOS, little is known about its degradation. The 26S proteasome is a large multisubunit protease responsible for the selective degradation of a number of short-lived regulatory proteins whose activity must be tightly regulated, such as NF-κB, STAT1, fos/jun and cyclins (11) (12) (13) . In this report, we identify the 26S proteasome as the major pathway responsible for human iNOS degradation. Human iNOS is targeted for degradation by the proteasome, notwithstanding its capacity to produce NO, dimerize or bind the substrate.
Furthermore, we demonstrate that the proteasome pathway regulates human iNOS at both transcriptional and post-translational levels. 
EXPERIMENTAL PROCEDURES
Reagents. Lactacytin, calpastatin, taurocholic acid were obtained from Calbiochem- 
RESULTS AND DISCUSSION

Human iNOS is a Target for the Proteasome Degradation Pathway.
We investigated the degradation pathway for iNOS in the HEK293 cell line; an epithelial cell line that does not express any of the NOS genes and has been extensively used to study exogenously expressed iNOS (14, 17) . We had previously produced an HEK293 cell line with stable expression of human iNOS (14) , henceforth referred to as HEK293-iNOS. We tested the effects of the potent yet non-specific proteasome inhibitors, ALLN and MG132, and of the highly specific proteasome inhibitor lactacystin on iNOS expression in this cell line (13, 18) . Cells were incubated with proteasome inhibitors or the corresponding vehicle for 20 h and then harvested by lysis on ice (see experimental procedures) (14) . Lactacystin, ALLN and MG132 blocked human iNOS degradation leading to its accumulation, which could be detected by immunoblotting of cell lysates with specific antibody for iNOS ( 
Lactacystin Blocks Human iNOS Degradation Independent of NO Production by iNOS.
In addition to its role in degradation of regulatory proteins, the 26S proteasome has been implicated 7 in the removal of faulty, misfolded and oxidatively inactivated cellular proteins (12) . In this context, we investigated whether or not the proteasomal degradation of human iNOS is dependent on NO production by iNOS. We tested the effect of lactacystin on iNOS expressed in HEK293-iNOS cells incubated in the presence or absence of the substrate analogue NOS inhibitor, N ω -nitro-L-arginine methyl ester (L-NAME) (19) . Incubation of cells in the presence of 3 mM L-NAME resulted in inhibition of NO synthesis by iNOS as estimated by measuring nitrite accumulation in culture media (data not shown). Incubation of cells with 10 µM lactacystin for 20 h blocked iNOS degradation in the presence or absence of L-NAME (Fig. 4) .
Similar results were obtained when the specific iNOS inhibitor S-ethylisothiourea (50 µM) was used instead of L-NAME (data not shown) (20) . These data suggest that the ability of iNOS to synthesize NO is not required for its targeting by the proteasome degradation pathway. , and of iNOS D280A (Fig. 5) . These results suggest that targeting of human iNOS by the proteasome degradation pathway is independent of the capacity of iNOS to dimerize or to bind the substrate.
Lactacystin Blocks Degradation of a Splice Variant and a Mutant of Human iNOS that Lack
Inhibitors of calpains, trypsin-like proteases and chymotrypsin-like proteases and lysosomal inhibitors do not block human iNOS degradation.
To investigate the roles of other cellular proteolytic pathways that might be involved in iNOS degradation, the effect of various degradation inhibitors was tested. Following 20 h incubation in the presence of the specific inhibitor, cells were immediately lysed by boiling in SDS-containing buffer. In contrast to proteasomal inhibitors, the calpain inhibitor calpastatin (5 µM), inhibitor of the trypsin-like proteases TLCK (100 µM), or inhibitor of the chymotrypsin-like proteases TPCK (50 µM) did not lead to accumulation of iNOS (Fig. 6A) . Similar results were obtained using the lysosmal protease inhibitors E64 (50 µM ), leupeptin (50 µM), the aspartate protease inhibitor pepstatin-A (100 µM), the lysosomal acidification inhibitors chloroquine (100 µM), or NH 4 Cl (20 mM) ( Fig. 6 B and C ). Yet, there was mild but not consistent increase iNOS detection with lysosomal inhibitors (Fig. 6) . Because of the mild increase seen in some of the iNOS immunoblot signals in figure 6 , a possible role for the lysosomal pathway in human iNOS degradation cannot be ruled out. As a positive control, lactacystin was used during the same experiments, and resulted in a more pronounced accumulation of iNOS suggesting that the proteasome pathway plays a primary role in human iNOS degradation.
The Proteasome Regulates iNOS Expression at Transcriptional and Post-Translational Levels: Lactacystin Prevents iNOS induction by cytokines. NF-κB is a major transcription factor
involved in the inducible expression of iNOS (22, 23) . It is a ubiquitous transcription factor that is activated by a myriad of proinflammatory stimuli and cytokines (24) . Proinflammatory stimuli activate NF-κB through a tightly regulated cascade of phosphorylation, ubiquitination and proteasomal proteolysis of a physically associated class of inhibitor molecules; the best characterized of which is IκBα. Therefore, proteasomal inhibitors block the degradation of already phyosphorylated and ubiquitinated IκBα, thus aborting NF-κB activation (25) .
Inhibitors of the proteasome pathway were found to interfere with the induction of iNOS in rat alveolar macrophages by blocking NF-κB activation (26) . We hypothesized that the proteasome regulates iNOS on two distinct levels; at the transcripitonal level, by degrading IκBα and thus hypothesis we used a cytokine mixture of IL-1β (0.5 ng/ml), TNF-α (10 ng/ml) and IL-6 (200 u/ml) to induce iNOS expression in RT4 cells (6, 15) . Addition of 40 µM lactacystin 1 h prior to stimulation prevented iNOS induction (Fig. 7A) . The inhibitory effect on iNOS induction was due to inhibition of IκBα degradation, as suggested by increased levels of IκBα (Fig. 7B) . The increase in IκBα seen with proteasomal inhibition was due to inhibition of the degradation of already phosphorylated IκBα as demonstrated by immunoblotting cell lysates with anti phospho-IκBα specific antibody (Fig. 7C ) (27).
Proteasomal Inhibition by Lactacystin Blocks iNOS degradation in RT4 Cells.
We hypothesized that in cells stimulated by cytokines to produce iNOS, once iNOS is produced, proteasomal inhibitors will block its degradation. To test this hypothesis, RT4 cells were incubated for 24 h in the presence of the same cytokine mixture used above, followed by 24 h incubation with fresh medium without cytokines and then in the presence of lactacytsin µM for 20 h). Treatment of cells with lactacystin led to a dose-dependent accumulation of iNOS (Fig. 8) , similar to that seen in experiments with transfected HEK293 expressing iNOS.
Thus, there is a dichotomous effect of proteasomal inhibition on cytokine-induced human iNOS. This phenomenon may have contributed to the lack of prior reports on human iNOS degradation. The finding that cytokine-induced iNOS in RT4 cells is degraded through the proteasome pathway indicate that the role of the proteasome pathway in iNOS degradation is not peculiar to HEK293 cells, nor is it likely to be simply a consequence of overexpression.
Proteasomal Inhibition Blocks murine iNOS degradation in RAW 264.7 Cells.
To extend the above observations to murine cells, we tested the effect of proteasomal inhibition on murine iNOS degradation. The murine macrophage cell line RAW 264.7 was stimulated by LPS (50 ng/ml) to induce iNOS expression (4, 6) . Forty-eight hours later, cells were incubated with lactacystin (40 µM for 20 h), in experiments similar to those described above for RT4 cells.
Lactacystin blocked murine iNOS degradation leading to its accumulation, as detected by
Western analysis (Fig 9A) and by increased iNOS activity, evaluated by measuring nitrite by guest on November 17, 2017 http://www.jbc.org/ Downloaded from accumulation in culture media (Fig. 9B) . These results indicate that targeting iNOS to the proteasome occurs in both human and murine cells and it occurs independent of the mechanism of iNOS induction, e.g., by transfection (HEK293), cytokines (RT4) or LPS (RAW 264.7).
Traditionally, it has been thought that all substrates of the proteasome pathway must be ubiquitinated as a prelude to their destruction. Recently, however, there have been several studies showing examples of proteins that are degraded by proteasomes independent of ubiquitination.
Moreover, as it has been demonstrated with p21, ubiquitination of a protein is no longer sufficient to conclude that its degradation must proceed through an ubiquitinated intermediate (28, 29) . In our study, it is not clear if the accumulated iNOS following proteasomal inhibition is ubiquitinated and whether or not ubiquitination of iNOS is required for its degradation. Higher molecular masses of proteins on immunoblots are often interpreted to be due to multiubiquitin conjugation (28, 29) . Higher molecular complexes of iNOS were observed in SDS/PAGE immunoblots, particularly following proteasomal inhibition (see figures 1, 2, 5 and 6). The identity of these complexes, however, remains to be elucidated. Potentially, acceleration of iNOS degradation may prove to be an efficient approach for NO modulation since the process of targeting cellular proteins for degradation is highly selective (11) (12) (13) . By characterizing the specific pathway for iNOS degradation, our study lays the groundwork for such endeavors. by guest on November 17, 2017 
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